Literature DB >> 19081304

Hepatitis B virus enhances interleukin-27 expression both in vivo and in vitro.

Chengliang Zhu1, Rui Zhang, Li Liu, Sahibzada T Rasool, Yongxin Mu, Wei Sun, Qian Hao, Fang Liu, Ying Zhu, Jianguo Wu.   

Abstract

The immune system plays important roles in determining the outcomes of hepatitis B virus (HBV) infection. Interleukin-27 (IL-27) is a recently identified pro-inflammatory cytokine produced by macrophages, dendritic cells, and epithelial cells. To determine the correlation between HBV infection and IL-27 expression, we investigated the serum IL-27 levels in patients with HBV infection and in healthy individuals. Results showed that IL-27 was significantly elevated in patients as compared to healthy individuals (P<0.001). IL-27 was also detected at higher levels in patients with liver cirrhosis or hepatocellular carcinoma than those with acute hepatitis B or chronic hepatitis B (P<0.05). We also found that IL-27 expression was influenced by HBV e antigen. In addition, our in vitro studies demonstrated that IL-27 promoter activity, mRNA and protein expression were all stimulated in cells transfected with infectious HBV clone.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19081304     DOI: 10.1016/j.clim.2008.10.011

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  22 in total

1.  IL-27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis.

Authors:  Nasim Akhtar Ansari; Rajiv Kumar; Shalini Gautam; Susanne Nylén; Om Prakash Singh; Shyam Sundar; David Sacks
Journal:  J Immunol       Date:  2011-02-28       Impact factor: 5.422

Review 2.  Modulation of inflammation by interleukin-27.

Authors:  Markus Bosmann; Peter A Ward
Journal:  J Leukoc Biol       Date:  2013-07-31       Impact factor: 4.962

3.  Interleukin-27 and IFNγ regulate the expression of CXCL9, CXCL10, and CXCL11 in hepatitis.

Authors:  Laëtitia Basset; Sylvie Chevalier; Yannic Danger; Muhammad Imran Arshad; Claire Piquet-Pellorce; Hugues Gascan; Michel Samson
Journal:  J Mol Med (Berl)       Date:  2015-07-23       Impact factor: 4.599

4.  Interleukin-27 acts on hepatic stellate cells and induces signal transducer and activator of transcription 1-dependent responses.

Authors:  Caroline Schoenherr; Ralf Weiskirchen; Serge Haan
Journal:  Cell Commun Signal       Date:  2010-08-19       Impact factor: 5.712

5.  Maintenance of CMV-specific CD8+ T cell responses and the relationship of IL-27 to IFN-γ levels with aging.

Authors:  Min Sun Shin; Jin Soo Lee; Naeun Lee; Won-Woo Lee; Sang Hyun Kim; Insoo Kang
Journal:  Cytokine       Date:  2012-12-29       Impact factor: 3.861

Review 6.  Evaluating the potential of IL-27 as a novel therapeutic agent in HIV-1 infection.

Authors:  Sanjay Swaminathan; Lue Dai; H Clifford Lane; Tomozumi Imamichi
Journal:  Cytokine Growth Factor Rev       Date:  2013-08-17       Impact factor: 7.638

7.  Evaluation of Serum and Gene Expression of Galectin-4, Interleukin-27, and Complement-7 in Hepatitis C Virus-Infected Egyptian Patients.

Authors:  Marwa S Abdel-Tawab; Hanan H Fouad; Dalia A Omran; Aml E Abdou; Shaimaa Mohamed Zaied; Alaa A Mohamed
Journal:  Biomed Res Int       Date:  2020-12-15       Impact factor: 3.411

8.  Enchanced levels of apolipoprotein M during HBV infection feedback suppresses HBV replication.

Authors:  Jin-Gang Gu; Cheng-liang Zhu; Duo-zhi Cheng; Yan Xie; Fang Liu; Xin Zhou
Journal:  Lipids Health Dis       Date:  2011-08-29       Impact factor: 3.876

9.  IL-27 in human secondary lymphoid organs attracts myeloid dendritic cells and impairs HLA class I-restricted antigen presentation.

Authors:  Fabio Morandi; Emma Di Carlo; Soldano Ferrone; Andrea Petretto; Vito Pistoia; Irma Airoldi
Journal:  J Immunol       Date:  2014-02-19       Impact factor: 5.422

Review 10.  New insights into IL-6 family cytokines in metabolism, hepatology and gastroenterology.

Authors:  Maria D Giraldez; David Carneros; Christoph Garbers; Stefan Rose-John; Matilde Bustos
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-07-01       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.